Invention Grant
- Patent Title: Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction
-
Application No.: US16960924Application Date: 2019-02-06
-
Publication No.: US11518764B2Publication Date: 2022-12-06
- Inventor: Rima Al-awar , Methvin Isaac , Anh My Chau , Ahmed Mamai , Iain Watson , Gennady Poda , Pandiaraju Subramanian , Brian Wilson , David Uehling , Michael Prakesch , Babu Joseph , Justin-Alexander Morin
- Applicant: Ontario Institute for Cancer Research (OICR)
- Applicant Address: CA Toronto
- Assignee: Ontario Institute for Cancer Research (OICR)
- Current Assignee: Ontario Institute for Cancer Research (OICR)
- Current Assignee Address: CA Toronto
- Agency: Bereskin & Parr LLP/S.E.N.C.R.L., s.r.l.
- Agent Sandra Marone
- International Application: PCT/CA2019/050154 WO 20190206
- International Announcement: WO2019/153080 WO 20190815
- Main IPC: A61K31/437
- IPC: A61K31/437 ; A61K31/519 ; C07D471/04 ; C07D487/04 ; C07D519/00 ; A61K45/06
Abstract:
The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
Public/Granted literature
- US20200331921A1 INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF Public/Granted day:2020-10-22
Information query
IPC分类:
